Compare · NAGE vs RLX
NAGE vs RLX
Side-by-side comparison of Niagen Bioscience Inc. (NAGE) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAGE and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $2.77B, about 10.7x NAGE ($258.7M).
- NAGE has been more active in the news (7 items in the past 4 weeks vs 4 for RLX).
- RLX has more recent analyst coverage (2 ratings vs 1 for NAGE).
- Company
- Niagen Bioscience Inc.
- RLX Technology Inc.
- Price
- $3.27+1.71%
- $1.79-1.10%
- Market cap
- $258.7M
- $2.77B
- 1M return
- +1.08%
- -
- 1Y return
- -67.53%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 7
- 4
- Recent ratings
- 1
- 2
RLX
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest NAGE
- Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
- Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
- Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
- SEC Form 10-Q filed by Niagen Bioscience Inc.
- Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
- Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
- Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
- Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
- Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited Second Quarter 2026 Financial Results
- RLX Technology to Report Second Quarter 2026 Financial Results on August 14, 2026
- SEC Form 4 filed by Chief Financial Officer Lu Chao
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate